12:00 AM
 | 
Jun 09, 2008
 |  BioCentury  |  Product Development

SGN-35 efficacy

SGN-35 efficacy

Data presented last week by Seattle Genetics (NASDAQ:SGEN) showed that SGN-35 doses of >=1.2 mg/kg led to an 86% overall response rate in patients with CD30-positive hematologic malignancies, most of whom had refractory or relapsed Hodgkin's lymphoma. For all doses of SGN-35, the overall response was...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >